- Business
- ChengDa PharmaCeuticals Co., Ltd. is a China-based contract research, development, and manufacturing organization (CRDMO) and fine chemical manufacturer specializing in active pharmaceutical ingredients (APIs), advanced pharmaceutical intermediates, and specialty nutritional additives. The company operates through two core business segments: Custom Development and Manufacturing (CDMO/CRDMO) Services and L-Carnitine Series Products. Its primary products and service offerings include customized process development, route scouting, analytical validation, and cGMP commercial manufacturing of small-molecule APIs and key registered intermediates for clinical and commercial-stage therapeutics targeting oncology, antiviral, central nervous system, cardiovascular, and metabolic disorders; pharmaceutical-grade levocarnitine (L-carnitine base), L-carnitine L-tartrate, acetyl-L-carnitine hydrochloride, L-carnitine hydrochloride, and L-carnitine fumarate used in medical formulations for cardiomyopathy and chronic renal disease; food, dietary supplement, infant nutrition, and animal feed additives; generic APIs and regulatory starting materials including brivaracetam and dapagliflozin intermediates; and specialized building blocks for emerging modalities, including phosphoramidite monomers and GalNAc delivery platform conjugates for oligonucleotide (siRNA/ASO) therapeutics, as well as intermediates for small-molecule GLP-1 receptor agonists. Founded in 1999 and headquartered in Jiashan County, Jiaxing, Zhejiang Province, China, the company distributes its products domestically and exports to more than 30 countries and regions across North America, Europe, and the Asia-Pacific region, operating manufacturing facilities compliant with international standards, including U.S. FDA, Japanese PMDA, and ISO/FSSC certifications. Recent corporate developments include the successful completion of an on-site U.S. FDA cGMP inspection with No Action Indicated (NAI) status at its Jiaxing manufacturing site in late 2024; a strategic minority equity investment of RMB 70 million in Chengdu Speikang Biomedical Technology Co., Ltd. in 2025 to strengthen contract research (CR) integration and API co-development; the expansion into regenerative medicine via its biopharmaceutical subsidiary Shanghai Jiuqiancheng Biomedical through a strategic technology licensing alliance with Chiron Pharma for stem cell therapies; and the completion, environmental validation, and commissioning of upgraded manufacturing lines and expanded research facilities for high-potency APIs, specialized intermediates, and L-carnitine derivatives.